Magnesium L-Threonate: Does It Actually Cross the Blood-Brain Barrier?

Magnesium L-Threonate, Defined

Magnesium L-threonate is a chelated salt form of magnesium. The magnesium ion is bound to two molecules of L-threonate, a natural metabolite of vitamin C. It was developed at MIT and introduced in a landmark 2010 Neuron paper. The branded commercial form is called Magtein.

In practical terms: like magnesium glycinate, citrate, and malate, magnesium L-threonate belongs to the broader family of organic magnesium salts. What sets it apart is its design intent. Most magnesium salt forms target whole-body repletion, correcting a dietary shortfall. Magnesium L-threonate was engineered around a different hypothesis: that the threonate ligand improves delivery of magnesium specifically into the central nervous system.

Why the threonate ligand matters

Each magnesium L-threonate molecule pairs one magnesium ion with two L-threonate molecules. L-threonate is an oxidized metabolite of L-ascorbic acid (vitamin C). The resulting chelate produces a neutral, lipophilic-leaning complex. That structural property is hypothesized to support transit across the blood-brain barrier more efficiently than ionic magnesium salts.

This is mechanistically distinct from the more familiar "organic vs. inorganic" bioavailability story. The glycinate vs. oxide debate is largely about gut absorption. The threonate story is about what happens after absorption, specifically, whether the magnesium reaches the brain. Early rodent data suggested the threonate ligand elevates intracellular brain magnesium, a claim that subsequent mechanistic work began to explore at the synapse level.

From MIT lab to supplement aisle

Magnesium L-threonate does not occur in meaningful quantities in food. It is synthesized chemically. The compound originated in the laboratory of Dr. Guosong Liu at MIT (with Inna Slutsky as first author of the seminal paper), where researchers were investigating whether raising brain magnesium could enhance synaptic (the gap between brain cells where signals pass) plasticity and memory. That 2010 Neuron paper became the scientific foundation for the product category.

The compound was subsequently licensed and commercialized as Magtein by Magceutics and later AIDP. A 2016 human trial followed, testing the branded form in older adults with cognitive complaints. That academic lineage (MIT origin, peer-reviewed publication, patented trademark) is central to how Magtein is marketed. It also means the evidence base and the commercial interest are closely intertwined, which matters when reading the trial data.

How Magnesium L-Threonate Is Proposed to Reach the Brain

The central hypothesis is straightforward. Oral magnesium L-threonate raises circulating magnesium. The threonate ligand then facilitates preferential delivery into the CNS. Higher intracellular brain magnesium is proposed to support synaptic density and NMDA-receptor-dependent plasticity. This pathway was first mapped in rodents, and subsequent work began to characterize how threonate regulates synapse density via intraneuronal magnesium concentration.

The proposed pathway: brain magnesium and synaptic density

In rodent models, oral magnesium L-threonate raised cerebrospinal fluid and brain magnesium concentrations more than other magnesium salts at comparable elemental doses. That elevation was associated with increased synaptic density and spatial memory. The proposed downstream mechanism runs through NMDA-receptor function. Magnesium acts as a voltage-dependent blocker of NMDA receptors; intracellular magnesium concentration shapes how efficiently those receptors support long-term potentiation. Recent work confirms intracellular magnesium enhances hippocampal plasticity. In animal models of Alzheimer's pathology, MgT prevented synaptic loss and reversed cognitive deficits.

Two important counterweights apply. First, a 2025 rat study in a hypothyroidism model found MgT reduced amyloid-β without cognitive improvement, a reminder that a favorable biomarker shift does not automatically translate into functional benefit. Second, an animal comparison study found that magnesium acetyl-taurate produced higher brain magnesium than MgT. The claim that magnesium L-threonate is uniquely superior at brain penetration is not a settled question.

Absorption, half-life, and the brain-magnesium question

On oral bioavailability, a systematic review of magnesium supplement forms confirms organic salts are more bioavailable than inorganic ones, magnesium L-threonate included. Plasma magnesium rises modestly after supplementation. The more important gap is between serum magnesium and what is actually happening in the brain. Serum magnesium is a known imperfect indicator of tissue magnesium status, and intracellular magnesium deficiency can coexist with apparently normal serum levels.

No human neuroimaging trial has confirmed that oral magnesium L-threonate specifically raises brain magnesium in people. Animal data supports magnesium modulating BBB permeability and amyloid-β transcytosis, and organoid research shows the BBB modulates its response to magnesium salts, but neither study is direct evidence that oral MgT crosses the human BBB at clinically meaningful concentrations. Half-life data for the threonate ligand specifically is sparse. In human trials, MgT has generally been taken with food, but formal timing pharmacokinetics are not well characterized.

What the MgT Trials Show

The claims behind magnesium L-threonate cover cognitive function in older adults with cognitive complaints, sleep quality, synaptic density and Alzheimer's-relevant pathology, and whether MgT actually elevates brain magnesium in humans.

Cognitive function in older adults with cognitive complaints: Limited

The central human trial is the 2016 MMFS-01 study: 44 adults aged 50-70 with self-reported cognitive complaints, randomized to 1.5-2 g/day Magtein for 12 weeks (MMFS-01 is a Magtein-based formula that also contained low-dose vitamin C and vitamin D3 to prevent baseline-deficiency confounding). Participants showed improvements on a cognitive composite score. The limitations are significant: small sample size, single site, and industry funding from the company that holds the Magtein patent. Independent replication has not yet been completed. A more recent 2025 RCT found improvements in cognition, working memory, and reaction time in adults aged 18–45 with self-reported sleep dissatisfaction, also industry-funded. Research suggests magnesium L-threonate may support cognitive performance in certain populations. That is a preliminary positive signal, not a settled cognitive intervention.

Sleep quality and daytime functioning: Limited

A 2024 RCT in approximately 80 adults with sleep complaints tested Magtein against placebo. Participants taking Magtein reported improvements in subjective sleep quality, mood, energy, and daytime functioning. Limitations include industry funding, reliance on subjective endpoints, and the absence of polysomnography to objectively confirm sleep architecture changes. Systematic review evidence on magnesium and sleep broadly shows uncertain associations across RCTs, and benefits appear most consistent in those with low magnesium status. The sleep signal from MgT trials is real but requires independent replication.

Synaptic density and Alzheimer's-relevant pathology: Animal-only

The preclinical evidence base here is substantial and consistent. Studies from 2010, 2014, and 2018, plus two papers from 2025 and a further 2025 paper, all demonstrate MgT-related effects on synaptic density, amyloid pathology, or neuroinflammation in rodent and mouse models. The mechanism is reproducible in animals. Human translation is not established. A 2025 hypothyroid rat model found reduced amyloid-β without cognitive improvement, an important reminder that preclinical biomarker changes do not guarantee functional benefit. MgT should never be framed as an Alzheimer's treatment or prevention strategy.

General brain-magnesium elevation in humans: Animal-only

Rodent studies from 2010 and 2016 demonstrated CSF and brain magnesium elevation following oral MgT. No human neuroimaging study has confirmed that oral magnesium L-threonate specifically raises brain magnesium in people. An animal comparison found magnesium acetyl-taurate produced higher brain concentrations than MgT, which means MgT's claimed superiority over other forms at brain penetration is not a settled question. The brain-penetration hypothesis is mechanistically plausible and supported by animal data, but it remains unconfirmed in humans.

What magnesium L-threonate is NOT shown to do:

• Treat, prevent, or reverse Alzheimer's disease or any cognitive disorder.
• Demonstrate human neuroimaging evidence of brain magnesium elevation.
• Substitute for clinically indicated treatment for diagnosed sleep disorders, depression, or anxiety.
• Demonstrate superiority over other magnesium salt forms on any human endpoint other than the cognition and sleep readouts above.

Magtein vs. Other Magnesium Forms

Not all magnesium supplements are interchangeable. Bioavailability varies dramatically, roughly 5-10x between magnesium oxide and well-absorbed organic salts. CNS-targeting claims exist only for magnesium L-threonate. For most people seeking general magnesium repletion, glycinate or citrate represent the more extensively studied options with decades of clinical use behind them.

• Magnesium L-threonate (Magtein). Branded Magtein supplies approximately 144 mg elemental magnesium per 2 g of Magtein; typical dose 1-2 g per capsule. The threonate ligand is designed around CNS penetration; plasma magnesium rises modestly. Quality flag: verify the "Magtein" trademark on the certificate of analysis, generic L-threonate sources are less characterized and may not match the studied compound.
• Magnesium glycinate (bisglycinate). Chelated to glycine; approximately 14% elemental magnesium by weight; typical 200-400 mg elemental per capsule. The most-studied form for subjective sleep and anxiety outcomes. Quality flag: verify bisglycinate rather than magnesium oxide blended with glycine, which is a common adulteration.
• Magnesium citrate. Approximately 16% elemental magnesium; commonly dosed at 200-400 mg elemental. Well-absorbed orally; the most-studied form for laxation and general repletion. Quality flag: confirm USP grade where available.
• Magnesium oxide. Approximately 60% elemental magnesium by mass but only around 4% bioavailable; the form found in most multivitamins. Useful for laxation; poorly suited for repletion or any CNS-related claim.

Third-party testing programs (USP, NSF International, and ConsumerLab) provide independent verification of label accuracy, contaminant screening, and dissolution testing. For magnesium L-threonate specifically, the Magtein trademark and patent lineage mean that products carrying that name should be traceable to the licensed ingredient. When evaluating any magnesium supplement, look for the third-party certification seal and request a certificate of analysis confirming the specific salt form. "Magnesium L-threonate" on a label without the Magtein trademark may not reflect the compound used in published trials. Different magnesium salt forms vary in absorption and clinical indication, and the form that fits one goal often differs from the form that fits another.

Regulatory Status: As of May 2026

Magnesium L-threonate is sold in the United States as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA). It is not FDA-approved for any medical indication. No FDA-authorized health claim exists for magnesium L-threonate in relation to cognition, sleep, or any neurological condition. The Magtein trademark is held by Magceutics and distributed through AIDP; the patent lineage is academically traceable to the MIT research group.

Magnesium L-threonate has attracted FTC attention in the broader context of cognitive-claim supplements, though no warning-letter pattern equivalent to actions taken against other supplement categories has been publicly documented for this specific compound as of this writing. Magnesium L-threonate is not on the World Anti-Doping Agency (WADA) prohibited list and is not restricted for competitive athletes. As with all dietary supplements, the FDA does not evaluate safety or efficacy before a product reaches market. Consumers bear the responsibility of verifying third-party testing and label accuracy.

Safety, Side Effects, and Drug Interactions

Large-scale, long-term safety data specific to magnesium L-threonate is limited. The available adverse event profiles come primarily from a 2016 dose-finding study, a 2024 placebo-controlled trial, and a 2025 follow-up, all relatively small, short-duration trials. The broader magnesium-salt safety record is more extensive and provides useful context.

Reported side effects

Across published MgT trials, the most commonly reported adverse events are gastrointestinal: loose stools and mild abdominal discomfort. These GI effects tend to be less pronounced with threonate and glycinate than with oxide or citrate, likely because the lower elemental magnesium load per dose reduces osmotic laxative effect. Headache and mild fatigue have been reported at low frequency in trial populations. No serious adverse events were attributed to MgT in the published human trials. Studies have reported these effects. That is not the same as establishing a comprehensive safety profile. At doses above the tolerable upper intake level for magnesium (350 mg elemental per day from supplements, per the National Institutes of Health), the risk of GI effects and, in vulnerable populations, hypermagnesemia increases regardless of salt form.

Drug interactions

• Bisphosphonates (e.g., alendronate, risedronate). Major. Magnesium chelates bisphosphonates in the gastrointestinal tract, substantially reducing bisphosphonate absorption and efficacy. Standard guidance is to separate dosing by at least 2 hours, but confirm timing with your prescriber or pharmacist.
• Fluoroquinolone antibiotics (e.g., ciprofloxacin, levofloxacin). Major. Magnesium forms insoluble chelates with fluoroquinolones in the gut, reducing antibiotic absorption and potentially compromising treatment of serious infections. Standard guidance is to separate dosing by at least 2 hours, but confirm timing with your prescriber or pharmacist.
• Tetracycline antibiotics (e.g., doxycycline, minocycline). Major. Same chelation mechanism as fluoroquinolones. Standard guidance is to separate dosing by at least 2 hours, but confirm timing with your prescriber or pharmacist.
• Diuretics (loop, thiazide, potassium-sparing): Moderate. Loop and thiazide diuretics increase urinary magnesium excretion; potassium-sparing diuretics may reduce it. Clinically relevant when magnesium supplementation and chronic diuretic therapy coexist, monitoring of serum magnesium is appropriate.
• Other CNS-active supplements. Theoretical. Magnesium L-threonate is frequently marketed as part of cognitive supplement stacks. Controlled human interaction data for these combinations is absent. Caution is warranted when combining multiple CNS-active compounds without clinical guidance.

Pregnancy, breastfeeding, and organ function

Dietary magnesium intake during pregnancy is well-characterized and generally safe within recommended ranges. Supplemental magnesium L-threonate specifically has no controlled human pregnancy data. Until that data exists, supplemental MgT doses during pregnancy are generally avoided. The same applies to breastfeeding. In renal impairment, particularly eGFR below 60 mL/min/1.73m², the kidneys' reduced ability to excrete excess magnesium creates a real risk of hypermagnesemia with any supplemental magnesium form. Clinical guidance is required before starting magnesium supplementation in this population. No specific hepatic concern has been documented for the threonate ligand. Pediatric dosing for magnesium L-threonate is not characterized; no pediatric trials exist.

Who Should Skip Magnesium L-Threonate

The following represent honest contraindications and high-caution scenarios, not a comprehensive risk list, but the clearest cases where starting MgT without clinical input is inadvisable.

• Pregnant or breastfeeding individuals, no controlled human safety data at supplemental MgT doses.
• Anyone with impaired renal function (eGFR <60), magnesium supplementation requires clinical guidance regardless of salt form.
• People currently taking bisphosphonates, fluoroquinolone or tetracycline antibiotics without a 2-hour separation plan.
• People with a diagnosed cognitive disorder hoping MgT substitutes for clinical evaluation or treatment.
• People with a diagnosed sleep disorder hoping MgT substitutes for evaluation, obstructive sleep apnea and primary insomnia warrant clinical workup, and insomnia specifically responds well to cognitive behavioral therapy (CBT-I) as a first-line intervention.
• Children, supplemental MgT doses are not characterized in pediatric populations.

If any of the above apply, do not start magnesium L-threonate without speaking to a clinician familiar with your full medication list and biomarkers.

Magtein vs. Glycinate, Citrate, Oxide: Side by Side

For someone choosing a magnesium salt, the practical question is: what does threonate uniquely target versus the more general-purpose forms? The answer comes down to design intent, and whether the human evidence behind that intent is strong enough to justify the premium.

• Source / chemistry. L-threonate: magnesium chelated to two L-threonate ligands (vitamin C metabolite). Glycinate: magnesium chelated to two glycine molecules. Citrate: magnesium salt of citric acid. Oxide: simple magnesium oxide.
• Bioavailability. L-threonate: comparable oral absorption to other organic salts; the CNS-penetration claim is the differentiator. Glycinate and citrate are well-absorbed organic forms. Oxide: poorly absorbed at approximately 4%.
• Strongest evidence. L-threonate: a 2016 cognition trial (N≈50, 12 weeks, older adults with cognitive complaints) and a 2024 sleep trial (N≈80, adults with sleep complaints). Glycinate: subjective sleep and anxiety trials. Citrate: laxation and general repletion. Oxide: laxation only.
• Studied dose range. L-threonate: 1.5-2 g/day Magtein in human trials. Glycinate: 200-400 mg elemental. Citrate: 200-400 mg elemental. Oxide: 250-500 mg elemental.
• Key safety differences. All four share GI risk at higher doses; threonate and glycinate tend to produce the fewest GI complaints; oxide and citrate are the most laxative at equivalent elemental doses.
• Cost (relative). L-threonate (Magtein): $$$. Glycinate: $$. Citrate: $. Oxide: $.
• Regulatory status. All sold as dietary supplements under DSHEA in the US; none carry an FDA-authorized health claim.

For someone whose primary interest is cognitive function or sleep, magnesium L-threonate is the form whose marketing claim aligns with its molecular design. But the human evidence is preliminary, the trials are small, and industry funding is present in every published RCT. For someone whose primary interest is general magnesium repletion or laxation, citrate or glycinate carries more decades-deep clinical use and a lower price point. The biomarker that would actually answer this question for any individual is serum magnesium, ideally paired with RBC magnesium where available. For day-to-day repletion or laxation, citrate and glycinate carry more decades-deep clinical use at a lower price point.

Biomarkers to Track With Magnesium L-Threonate

Serum magnesium is the most accessible readout, but it is a known-imperfect proxy for tissue and brain magnesium status. Serum levels frequently appear normal even when intracellular stores are depleted, and intracellular magnesium deficiency can coexist with serum values in the reference range. RBC magnesium provides a longer-window picture of cellular status. Establishing a baseline before starting supplementation, and retesting at 8-12 weeks, gives the most interpretable signal.

• Serum magnesium: Reflects current circulating magnesium. Updated reference ranges place the lower bound at 0.85 mmol/L, a threshold associated with reduced dementia risk in systematic review data. Limitation: serum levels frequently appear "normal" even when intracellular and brain stores are low. A modest upward shift at 8-12 weeks may be visible if supplementation is meaningfully affecting whole-body magnesium status.
• RBC magnesium: Reflects longer-window cellular magnesium status. More sensitive than serum to chronic insufficiency; the marker most likely to show whether daily supplementation has actually moved tissue magnesium over time.

When Cognitive or Sleep Concerns Deserve a Clinician, Not a Supplement

Persistent cognitive complaints, worsening memory, chronic insomnia, or symptoms that could reflect early neurological change deserve clinical evaluation, not a supplement as a first response. For cognitive concerns, a primary-care workup covering CBC, comprehensive metabolic panel, thyroid function, B12, vitamin D, and depression screening is the appropriate starting point. For chronic insomnia or suspected sleep apnea, a sleep-medicine consult, not a magnesium trial, is the right first step. Bloodwork is the objective foundation that makes any subsequent supplement decision interpretable rather than speculative.

That principle, measuring biology before acting on it, is the foundation of Superpower's approach to preventive health. In a magnesium-supplement market this broad and this lightly regulated, a measured baseline is the most reliable starting point, whether or not magnesium L-threonate turns out to be the right tool for what you are trying to address.